Inozyme Pharma, Inc.: M&A transaction — BioMarin completes acquisition of Inozyme for $4.00 per share; Inozyme to delist

Inozyme Pharma, Inc.

BioMarin completed tender offer acquiring 69.8% of Inozyme shares at $4.00/share cash; subsequent merger completed July 1, 2025.
Inozyme will delist from Nasdaq and deregister under Exchange Act; Form 15 to be filed.
All Inozyme directors resigned; G. Eric Davis, Eric Fleekop, Brian Mueller appointed to board.
Executive officers resigned; G. Eric Davis became President, Eric Fleekop became Secretary.
In-the-money stock options and RSUs accelerated and cashed out at $4.00/share.

item 1.02 item 2.01 item 3.01 item 3.03 item 5.01 item 5.03 item 5.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.95

Inozyme Pharma, Inc. completed an acquisition involving BioMarin Pharmaceutical Inc. for not specified in excerpt (closed 2025-07-01).

Action: acquisition
Counterparty: BioMarin Pharmaceutical Inc.
Consideration: not specified in excerpt
Closing: 2025-07-01

Exact text from the filing

On July 1, 2025, BioMarin Pharmaceutical Inc., a Delaware corporation (“ BioMarin ”) completed its acquisition of Inozyme Pharma, Inc., a Delaware corporation (the “ Company ” or “ Inozyme ”) pursuant to an Agreement and Plan of Merger, dated May 16, 2025

View on SEC.gov

Browse all m&a transactions →

Source: SEC EDGAR

accession 0001193125-25-153582

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.